Table 4 –
Association of presence of cirrhosis with all-cause 30-day mortality in all CLD patients who tested positive for SARS-CoV-2 infection (Cirrhosis/Positive versus Non-Cirrhosis/Positive)
| Univariable Cox Regression | Multivariable Cox Regression | |||||
|---|---|---|---|---|---|---|
| HR | 95% Cl | P-Value | aHR | 95% Cl | P-Value | |
| Presence of Cirrhosis | 5.57 | 4.94–6.29 | <0.01 | 3.39 | 2.96–3.89 | <0.01 |
| Age (years) | 1.07 | 1.06–1.07 | <0.01 | 1.05 | 1.05–1.06 | <0.01 |
| Female | 0.65 | 0.58–0.73 | <0.01 | 0.84 | 0.74–0.95 | <0.01 |
| Race/Ethnicity | ||||||
| White | Ref | Ref | ||||
| Black/African-American | 1.29 | 1.11–1.51 | <0.01 | 1.06 | 0.90–1.24 | 0.52 |
| Hispanic | 0.90 | 0.77–1.07 | 0.23 | 1.33 | 1.13–1.57 | <0.01 |
| Asian | 0.97 | 0.69–1.36 | 0.85 | 1.28 | 0.90–1.83 | 0.16 |
| Unknown/Other | 1.38 | 1.11–1.71 | <0.01 | 1.61 | 1.29–2.00 | <0.01 |
| Etiology of Liver Disease | ||||||
| NAFLD | Ref | Ref | ||||
| Hepatitis C | 1.86 | 1.60–2.16 | <0.01 | 1.22 | 1.04–1.43 | 0.02 |
| AALD | 2.50 | 2.15–2.90 | <0.01 | 1.28 | 1.08–1.51 | <0.01 |
| Hepatitis B | 1.43 | 1.08–1.90 | 0.01 | 1.00 | 0.75–1.34 | 0.99 |
| Cholestatic | 1.98 | 1.34–2.91 | <0.01 | 0.73 | 0.50–1.09 | 0.12 |
| Autoimmune | 2.05 | 1.40–2.99 | <0.01 | 1.12 | 0.76–1.64 | 0.58 |
| Charlson Comorbidity Index | 1.18 | 1.16–1.19 | <0.01 | 1.06 | 1.05–1.08 | <0.01 |
| Region | ||||||
| Northeast | Ref | Ref | ||||
| Midwest | 0.64 | 0.51–0.79 | <0.01 | 0.58 | 0.47–0.72 | <0.01 |
| South | 0.86 | 0.70–1.06 | 0.15 | 0.87 | 0.70–1.07 | 0.19 |
| West | 0.45 | 0.34–0.60 | <0.01 | 0.54 | 0.40–0.72 | <0.01 |
| Other | 0.59 | 0.50–0.71 | <0.01 | 0.55 | 0.46–0.66 | <0.01 |
Abbreviations: AALD, alcohol-associated liver disease; aHR, adjusted hazard ratio; CI, confidence interval; HR, hazard ratio; NAFLD, non-alcoholic fatty liver disease.